A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 558 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR CancerLand Bookshelf : Loosen July 26, 2021 Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting... July 16, 2021 How I Navigated Being a Young Mom During Cancer: A Survivor’s... February 15, 2023 New on NCI’s Websites for December 2020 December 31, 2020 Load more HOT NEWS Cancer Rehabilitation Starts at Diagnosis Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... Can Getting a “Base Tan” Protect You From Sunburn and Skin... Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus...
